登录查看更多内容

Salvage metronomic chemo-endocrine treatment for pretreated metastatic luminal breast cancer

Piotr J. Wysocki

MD, PhD, medical oncologist; Professor of Medicine, Head of Department of Oncology, Jagiellonian University Hospital. ASCO International Affairs Committee member

发布日期: 2023年2月26日

Metronomic chemo-endocrine therapy for pretreated endocrine-resistant luminal breast cancer patients provides a salvage option with a very good safety profile. Many breast cancer patients who failed endocrine therapy but remain ER-positive and also failed various options of standardly dosed chemotherapy (usually monotherapy or dublets) experience at least disease stabilization with chemotherapy triplet combined with fulvestrant.?

要查看或添加评论，请登录

Piotr J. Wysocki的更多文章

[89Zr]Zr-girentuximab, a carbonic anhydrase 9 PET tracer, is highly sensitive and specific for clear-cell RCC imaging

2024年9月13日

[89Zr]Zr-girentuximab, a carbonic anhydrase 9 PET tracer, is highly sensitive and specific for clear-cell RCC imaging

A phase 3 trial, ZIRCON, evaluated the use of the monoclonal antibody [89Zr]Zr-girentuximab for PET-CT imaging of…

1 条评论
IPMN-derived pancreatic cancer patients benefit from adjuvant chemotherapy only in the case of nodal involvement and elevated preoperative CA19.9

2024年9月11日

IPMN-derived pancreatic cancer patients benefit from adjuvant chemotherapy only in the case of nodal involvement and elevated preoperative CA19.9

A recent international multicenter study published in the Journal of Clinical Oncology by Habib Joseph R et al…

1 条评论
Trimodality therapy for High-Grade T1 BCG-resistant bladder cancer represents a promising alternative to radical cystectomy.

2024年9月4日

Trimodality therapy for High-Grade T1 BCG-resistant bladder cancer represents a promising alternative to radical cystectomy.

Douglas M. Dahle and coauthors published the results of a study investigating the efficacy of trimodality therapy as an…

1 条评论
Belzutifan represents an active treatment option in highly pretreated ccRCC patients.

2024年9月3日

Belzutifan represents an active treatment option in highly pretreated ccRCC patients.

Toni Choueri et al published the results of a phase III LITESPARK-005 study comparing belzutifan with everolimus in…

1 条评论
Older patients with metastatic colorectal cancer treated with fluoropirimidine+bevacizumab combination do not benefit from the addition of oxaliplatin

2024年8月28日

Older patients with metastatic colorectal cancer treated with fluoropirimidine+bevacizumab combination do not benefit from the addition of oxaliplatin

A recent phase III clinical trial published in the Journal of Clinical Oncology has evaluated the effectiveness of…

2 条评论
Supervised, structured, and individualized exercise has a significant positive impact on the quality of life of metastatic breast cancer patients

2024年8月9日

Supervised, structured, and individualized exercise has a significant positive impact on the quality of life of metastatic breast cancer patients

A recent study published in Nature Medicine, led by Anouk E. Hiensch, demonstrates that supervised, structured, and…

1 条评论
Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer

2024年8月6日

Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer

A recent phase II clinical trial conducted across five institutions in Japan has investigated the efficacy of…

1 条评论
Aspirin reduces the risk of colorectal cancer in individuals with unhealthy lifestyle

2024年8月2日

Aspirin reduces the risk of colorectal cancer in individuals with unhealthy lifestyle

A study published in JAMA Oncology investigated the association between aspirin use and colorectal cancer (CRC)…

2 条评论
Combining PSMA-PET and PROMISE accurately stratifies high-risk and low-risk groups for overall survival in early and late stages of prostate cancer

2024年7月31日

Combining PSMA-PET and PROMISE accurately stratifies high-risk and low-risk groups for overall survival in early and late stages of prostate cancer

A recent multicentre retrospective study aimed to evaluate the effectiveness of PSMA-PET imaging and the PROMISE…

1 条评论
Patients with low genomic risk, unlike those with high risk, benefit from extended adjuvant endocrine therapy

2024年7月26日

Patients with low genomic risk, unlike those with high risk, benefit from extended adjuvant endocrine therapy

A recent study published in the Journal of Clinical Oncology assessed the utility of the 70-gene MammaPrint (MP) assay…

1 条评论

See all articles

Salvage metronomic chemo-endocrine treatment for pretreated metastatic luminal breast cancer

Piotr J. Wysocki

MD, PhD, medical oncologist; Professor of Medicine, Head of Department of Oncology, Jagiellonian University Hospital. ASCO International Affairs Committee member

Piotr J. Wysocki的更多文章

社区洞察

其他会员也浏览了

Plasma #hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma.

1st Line Letrozole and Denosumab therapy of a 73-year-old caucasian female with metastatic Breast Cancer (Positive Estrogen Receptor)

Electrochemotherapy in treatment of Melanoma & Skin cancers

Breakthrough in Cervical Cancer Treatment Cuts Death?Risk?by?40%

Salvage brachytherapy for second ipsilateral breast tumor event: Relating dosimetric analysis to late side effects

From Xenoestrogens to Endocrine Disruptors: Everyday Toxins Linked to Breast Cancer

DATO-DXd SIGNIFICANTLY IMPROVES OUTCOMES OF PRETREATED ER+/HER2- BREAST CANCER PATIENTS

5-year survival in gastric adenocarcinoma with epithelial and stromal versican expression

Maintenance Chemotherapy Extends Life for Children With a Rare Cancer

Let's combine PI3Kβ inhibitors with immunotherapy for the treatment of PTEN-deficient breast cancer:

Piotr J. Wysocki的更多文章

[89Zr]Zr-girentuximab, a carbonic anhydrase 9 PET tracer, is highly sensitive and specific for clear-cell RCC imaging

IPMN-derived pancreatic cancer patients benefit from adjuvant chemotherapy only in the case of nodal involvement and elevated preoperative CA19.9

Trimodality therapy for High-Grade T1 BCG-resistant bladder cancer represents a promising alternative to radical cystectomy.

Belzutifan represents an active treatment option in highly pretreated ccRCC patients.

Older patients with metastatic colorectal cancer treated with fluoropirimidine+bevacizumab combination do not benefit from the addition of oxaliplatin

Supervised, structured, and individualized exercise has a significant positive impact on the quality of life of metastatic breast cancer patients

Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer

Aspirin reduces the risk of colorectal cancer in individuals with unhealthy lifestyle

Combining PSMA-PET and PROMISE accurately stratifies high-risk and low-risk groups for overall survival in early and late stages of prostate cancer

Patients with low genomic risk, unlike those with high risk, benefit from extended adjuvant endocrine therapy

社区洞察

其他会员也浏览了

Plasma #hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma.

1st Line Letrozole and Denosumab therapy of a 73-year-old caucasian female with metastatic Breast Cancer (Positive Estrogen Receptor)

Electrochemotherapy in treatment of Melanoma & Skin cancers

Breakthrough in Cervical Cancer Treatment Cuts Death?Risk?by?40%

Salvage brachytherapy for second ipsilateral breast tumor event: Relating dosimetric analysis to late side effects

From Xenoestrogens to Endocrine Disruptors: Everyday Toxins Linked to Breast Cancer

DATO-DXd SIGNIFICANTLY IMPROVES OUTCOMES OF PRETREATED ER+/HER2- BREAST CANCER PATIENTS

5-year survival in gastric adenocarcinoma with epithelial and stromal versican expression

Maintenance Chemotherapy Extends Life for Children With a Rare Cancer

Let's combine PI3Kβ inhibitors with immunotherapy for the treatment of PTEN-deficient breast cancer: